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Abstract. Cyclic peptides form an interesting class of compounds for study by conforma-
tional analysis, by virtue of their unique conformational features and biological properties.
The small cyclic peptides having 3–6 peptide units in their ring, show a variety of 
conformational characteristics such as occurrence of cis peptide units, flexibility of peptide 
dimension and variety in hydrogen bonding. The different possible conformations of cyclic tri- 
and hexa-peptides are given and certain specific conformational features are discussed for
cyclic tetra and pentapeptides. For higher cyclic peptides, the hydrogen bonding requirement
for stability of the backbone of the ring, is seen to be kept to a minimum. These various features 
and their significance are examined and discussed in the light of energy minimization studies 
and analysis of available experimental data.
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Introduction 
 
Cyclic peptides offer an interesting class of compounds for study using conformational 
methods. The condition of ring closure brings about restrictions on the possible 
conformations compared to a linear peptide. Still it is possible to have a considerable 
variety of conformations. In the last few years there has been a steady increase in the 
number of cyclic peptides studied both in solution and solid state as well as by 
conformational means. In this paper an attempt has been made to review and analyse 
the available information, with special emphasis on symmetry and hydrogen bonding. 
A number of review articles dealing with various aspects of cyclic peptides are available 
in literature and particular mention can be made of Karle (1981a), Kessler (1982), 
Ovchinnikov and Ivanov (1982).
 
Cyclic tripeptides 
 
Cyclic tripeptides which contain nine membered rings are in general strained systems 
Not many cyclic tripeptides are known. Those on which crystal structure information is 
available are cyclo trisarcosyl (Groth, 1976a) and others containing Prolyl and N- 
BzlGlycyl residues. One common feature in all these is the occurrence of cis peptide 
units which is geometrically a necessary factor for the formation of cyclic tripeptides. 
Earlier conformational studies on cyclic tripeptides have been done by Venkatachalam 
(1968), who has considered a three-fold symmetric conformation. Recent extensive 
work in our laboratory (Manjula, 1976; Ramnarayan, K. and Ramakrishnan, C.,
unpublished results) indicates three distinct conformations that are possible for a cyclic 
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tripeptide. These are shown in figure 1, in which the principal torsional angles are also 
marked. Figure la shows the symmetric form and lb an asymmetric form. These two 
are composed of three cis peptide units. The conformation shown in figure 1c has a rare 
feature of a trans peptide unit in combination with two cis peptide units.
The symmetric conformation is energetically more favourable than the other two. An 
 
 
Figure 1. Projection of the minimum energy conformations of cyclic tripeptides. 
A.  Three fold symmetric conformation with all three cis peptide units  
B.  Nonsymmetric conformation with all three cis peptide units   
 
C.  Nonsymmetric conformation with two cis and one trans peptide units. 
 
The bond angles (°) NCαC and the torsion angles (°) about the bonds are also given.
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interesting aspect of both symmetric and asymmetric conformations is that the φ value 
at all the α-carbon atoms are such that they are automatically suitable for the 
accommodation of a Prolyl residue which is very well known to take up cis form with 
equal ease as trans form. While the symmetric form can accommodate only homo- 
isomeric form of Prolyl residue (all L or all D), the asymmetric form can accommodate 
only a heterogeneous sequence (LLD or DDL). This is well supported by observation 
in that the conformations of the compounds cyclo-tri-L-Prolyl (Druyan et al., 1976) 
and cyclo(L-Pro-L-Pro-L-Hypro) (Kartha and Ambady, 1975) take up the symmetric 
(or near symmetric) form and that of cyclo (L-Pro-L-Pro-D-Pro) (Bats and Fuess, 
1980) and cyclo (L-Pro-BzlGly-D-Pro) (Kessler et al., 1983a) take up the asymmetric 
form. 
Kessler and his group have done extensive studios both in solution and solid state, on 
cyclic tripeptides containing NBzlGly and Prolyl residues. While cyclo (BzlGly-L-Pro- 
L-Pro) (Bats and Fuess, 1982) and cyclo(BzlGly2-L-Pro) (Bats and Fuess, 1980) take up 
symmetric conformations as would be expected, cyclo (Nitro BzlGly-L-Pro2) assumes 
the asymmetric conformation in the solid state (Kessler et al., 1983b), though this can 
easily be accommodated in a symmetric form. The reason for this is still not clear and 
needs further study. 
Another noteworthy feature of both the ‘all-cis’ conformations is that none of the 
N-H groups points inside the ring and hence there will not be steric hindrance if the 
hydrogen is substituted by other groups such as methyl, benzyl, etc. Such N-substituted 
groups are also known for their occurrences in cis peptide units.
It has been shown by Venkatachalam (1968) that the rather strong steric hindrance 
that exists between the Hαs in the symmetric conformation can be relieved by tilting the 
Cα-Hα vectors away from the centre of the ring. Though to some extent the short 
contacts are relieved by this process, there results undue distortion of the bond angles at 
Cα atoms. On the other hand, Manjula (1976) has shown that a large nonplanarity of the 
order of 20–30° can relieve this short contact without much distortion at the α-carbon 
atom. There is a third possibility, namely, the peptide dimensions can be suitably 
changed in order to provide more space in the centre of the ring. Recent energy 
minimization studies in our group (to be published), do indicate that an increase in the 
internal peptide bond angles CαCN and CNCα will be preferred to either large 
nonplanarity or large distortion of the bond angles at Cα. The average values of some of 
the bond lengths and bond angles of the cis peptide unit that occurs in different 
molecules are given in table 1, in which the standard dimensions are those given by 
Ramachandran and Venkatachalam (1968) and Ramachandran and Sasisekharan 
(1968). It can be seen that the bond lengths Cα–C and C–N are marginally higher and 
the bond angles CαCN and CNCα are definitely higher than the standard value for cyclic
tripeptides, while this is not so in the case of cis peptide units occurring in other (non tri) 
cyclic peptides (a more detailed analysis will be published elsewhere). The values 
obtained in the energy minimization studies for these angles are 121° and 129° 
respectively, which are on the higher side too. From these it can be concluded that the 
cis peptide unit has undergone slight expansion of the angles in order to provide space 
for the Hα atoms to be accommodated without steric hindrance. Thus the cis peptide
unit, while remaining reasonably rigid in other cyclic peptides, has shown tendency for 
need based flexibility in cyclic tripeptides. In fact, in a recent crystal structure 
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Table 1. Average dimensions of the cis peptide unit under different
conditions. 
 
 
 
determination of a cyclic tripeptide (Kessler, 1983b) one of the values of the angles
CαCN is as high as 135° and that of CNCα is 131°.
 
 
Cyclic tetrapeptides 
 
Cyclic tetrapeptide consisting of a ring system of 12 atoms, is less strained than a cyclic 
tripeptide. This is the smallest cyclic peptide which can be formed with all trans peptide 
units. The crystal structure information on cyclic tetrapeptides (Groth, 1970; Declercq 
et al., 1975; Flippen and Karle, 1976; Ueno and Shimizu, 1983; Swepston et al., 1981; 
Chiang and Karle, 1982) indicates a preponderance of Sarcosyl and Prolyl residues, 
which have nearly equal preference for cis and trans peptide units. Conformations with 
all trans peptide units (Ramakrishnan and Sarathy, 1968) and conformations with 
alternating cis and trans peptide units (Manjula and Ramakrishnan, 1979) can be 
formed with planar units and having different symmetry elements in the molecule.
Among the crystal structure studies, cyclo(L-Pro-Sar)2 (Ueno and Shimizu, 1983) 
prefers an all cis conformation, while dihydrochlamydocin (Flippen and Karle, 1976) 
favours an all trans structure, inspite of its having a Prolyl residue. A study of the 
Sarcosyl containing cyclic peptides clearly shows that the backbone rings of the 
cyclic peptides contain atleast one cis peptide unit each. 
Four of the cyclic tetrapeptides contain Prolyl residues: dihydrochlamydocin
(Flippen and Karle, 1976), cyclo (L-Pro-Sar)2 (Ueno and Shimizu, 1983) and cyclo (L-
Ala-L-Pro-L-Phe-L-Pro) (Chiang and Karle, 1982). Among these dihydrochlamydocin 
alone does not contain a cis peptide unit. The reason for this is the presence of an Aib 
residue in the sequence. Had this compound taken up a cis-trans-cis-trans structure, 
then Aib must occupy either a trans-cis junction or a cis-trans junction. Recent studies 
indicate that Aib residues cannot be easily accommodated in such a heterogeneous 
junction without serious steric hindrance. Even with the trans-trans junction the 
sterically allowed regions for an Aib residue in the (φ, ψ) plane is very restricted and 
centred around the α -helical regions. Recently Kawai et al (1983) have proposed a 
trans-trans-trans-cis conformation for Ala4 chlamydocin and it is satisfying to note that 
Aib occurs at a trans-trans junction.
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Earlier studies on cyclic tetrapeptides with four-fold and two-fold symmetric 
conformations have not yielded any hydrogen bonding within the ring, whereas the 
only observed all trans conformation of dihydrochlamydocin contains two γ-turns in 
the ring having two 3→1 hydrogen bonds. The reason for this can be sought in the 
sequence of this compound cyclo(Iabu-L-Phe-D-Pro-LX) which has got a Pro and an 
Aib occurring diagonally across in the sequence. Both of these are capable of 
supporting a γ-turn in a dipeptide. The energy map of a pair of two linked peptide units 
with Aib at the junction α-carbon atom has been worked out by Narasinga Rao (1982), 
who has taken into account the hydrogen bond energy too. This map shows that the 
minimum at the γ-turn region is only about 2 kcal mol–1 higher than the global energy 
minimum occurring at the α-helical regions of the map. Hence Aib can take up this 
conformation without much difficulty if this is going to help in the formation of the
cyclic ring. 
 
 
Cyclic pentapeptides 
 
The stability of a cyclic pentapeptide ring can be achieved by different schemes 
of hydrogen bonding. The two types of well known hydrogen bonding namely 4→1 
(β-turn) and 3→1 (γ-turn) are easily possible in cyclic pentapeptides. One can have a 
wide variety of conformations that can be worked out from energy considerations. 
Ramakrishnan and Narasinga Rao (1982) and Narasinga Rao (1982) have given the 
details of the different conformations that one can have in cyclic pentapeptide.
Observationally, crystal structures of five compounds are known. They are: 
cyclo (Gly-L-Pro-Gly-D-Ala-L-Pro) (Karle, 1978), cyclo (Gly-L-Pro-L-Ser-D-Ala-L- 
Pro) (Karle, 1979), cyclo(D-Phe-L-Pro-Gly-D-Ala-L-Pro) (Karle, 1981b), cyclo(L-Thr- 
D-Val-L-Pro-Sar-Me-Ala) (Mauger et al., 1982) and cyclo (D-Phe-L-Pro-Gly-D-Ala- 
L-Pro) (Karle, 1984). In all these cases there is a β-turn with a 4→1 hydrogen bond in 
the cyclic pentapeptide ring. Four of the five compounds have got two Prolyl residues in 
their sequence. Since proline is well known to bring about β-turns, it is not surprising 
that all these compounds have favoured a 4→1 hydrogen bond in their ring. 
Conformational studies on cyclic pentapeptides with β-turns (Manjula and 
Ramakrishnan, 1979) show that when three units of a cyclic pentapeptide are in β-turn 
orientation, the remaining two peptide units have a near γ-turn conformation. 
However, an actual βγ arrangement can be brought about only with significant 
nonplanarity in atleast one of the peptide units involved in the γ-turn (Narasinga Rao, 
1982). It is interesting to note that the residue at the centre of the γ-turn is proline both 
in the case of cyclo(Gly-L-Pro-Gly-D-Ala-L-Pro) and cyclo(D-Phe-L-Pro-Gly-D-Ala- 
Pro). 
Hence it can be concluded that a combination of nonplanarity, ring closure condition 
and occurrence of Prolyl residue at the proper place in the sequence has resulted in an 
additional hydrogen bond of the type 3→1, thereby increasing the stability. It will be 
interesting to watch for any cyclic pentapeptide that will take up βγ conformation in 
solid state without a Prolyl residue at the γ-turn centre. Such a structure can throw 
more light on any change in peptide dimensions and nonplanarity requirements for a 
cyclic pentapeptide. 
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Cyclic hexapeptides 
 
Amongst all cyclic peptides, small or big, cyclic hexapeptides have been studied most 
extensively by experimental methods. This is mainly owing to the ease of synthesis of 
cyclic hexapeptides and the ability of the cyclic hexapeptide backbone to take up well 
defined and stable structures, with all the peptide bonds in trans configuration, 
relatively easily. A recent review on cyclic peptides (Ovchinnikov and Ivanov, 1982) 
gives a list of more than 100 synthetic cyclic hexapeptides. An examination of the 
observed crystal structures shows that cyclic hexapeptides with no sequence symmetry 
and those of the type (A1–A2–A3)2, where Al , A2 and A3 are various amino acid
residues, take up conformations featured by two β-turns, many of which are stabilized 
by their associated hydrogen bonds. Table 2 gives a list of β-turns observed in cyclic 
hexapeptide structures as obtained from crystal structure studies. It can be seen that the 
 
 
Table 2.   β-turns in cyclic hexapeptides*.
 
 
? Not all the β-turns have a 4→1 hydrogen bond. 
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cyclic hexapeptide backbones are made up of different combinations of type I and II β- 
turns or their inverses and these can be classified into different categories as follows: 
 
(a) Cyclic hexapeptides made up of tripeptide fragments having the same type of 
β-turns, giving rise to near or exact two-fold symmetric cyclic hexapeptides. The 
first six cyclic hexapeptides given in table 2 are of this category.
(b) Cyclic hexapeptides made up of dissimilar β-turn tripeptide fragments: These can 
be further divided into two types in which:
(i) The two tripeptides fragments have β-turns, one being inverse to the other 
(Ι, I', II, ΙI') . Examples of such cyclic hexapeptides are given in entries 7–14 of 
table 2. 
(ii) The two β-turns are completely dissimilar. The entries 15–24 of the table 2 
can be seen to fall under this category, some of which are combinations of one 
type I β-turn and one type II β-turn, while the others (21–23 of table 2) have a 
type I β-turn and a type II' β-turn.
 
From the NMR studies of cyclic hexapeptides in solution, it has been found that one 
of the major conformations of cyclic hexapeptides especially of the type c(A1–A2–A3)2 
is one which has an average two-fold molecular symmetry and is stabilized by hydrogen 
bonded β-turns (see for example Gierasch et al., 1981; Kopple et al., 1978; Blaha and 
Budesinsky, 1973; Bovey et al., 1972; Torchia et al., 1972a,b).
The various possible conformations of cyclic hexapeptides can be obtained by using
stereochemical criteria and energy calculations. The earliest work in this group using 
energy calculations had been on six-fold symmetric cyclic hexapeptides and on two-fold 
symmetric cyclic hexapeptides having types I and II β-turns (Ramakrishnan and 
Sarathy, 1969; Sarathy and Ramakrishnan, 1971). Recently using energy minimization 
techniques, the accommodation of different hydrogen bonded secondary structural 
features like β-turns and γ-turns in the cyclic hexapeptide backbone were studied, and a 
summary of the results is given below:
 
(a) Different combinations of type I, II, I' and ΙI' β-turn tripeptide fragments can be 
linked to form geometrically and energetically feasible cyclic hexapeptides. 
Different subtypes are possible for each of these combinations and these depend 
mainly on: 
(i) The conformation at the Cαs where the two tripeptides link and (ii) in the 
hydrogen bonding schemes of the β-turn tripeptide itself. The conformations 
at the linking Cαs has been found to be either in the extended region or in the 
3→1 hydrogen bonded (γ or inverse γ) regions of the (φ, ψ) map. The different 
hydrogen bonding schemes found present in the component β-turns of these 
theoretically worked out cyclic hexapeptides are: 
(i)  A β-turn with only a 4→1 hydrogen bond 
(ii) A type I or I' β-turn having a 4→1 and a 3→ 1 hydrogen bonds occurring
in a bifurcated form of the type 
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Figure 2.  (a–e) 
 Cyclic peptides 247
 
 
Figure 2.  Stereodiagrams of cyclic hexapeptides with different hydrogen bonding schemes,
worked out using energy minimization studies: a to f has a pair of β turns.
(a), Type I--I (b), Type II-II (c),Type I–II; (d),Type Ι–ΙI', (e),Type Ι-I'; (f),Type II-II'; 
(g), Three fold symmetrical having three γ turns; (h), S6 symmetrical having three γ turns and 
three inverse γ turns. 
The hydrogen bonds are shown as broken lines. 
 
(iii) A type II.or II' β-turn having both the 4→1 and 3→1 hydrogen bonds 
formed with the same acceptor oxygen atom i. e., 
Figure 2a–f shows examples of cyclic hexapeptides made up of different combi- 
nation of b –turns alongs with their various hydrogen bonding schemes.
 
Figure 2.    (f–h)
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Another class of cyclic peptides of the sequence type c(A1–A2)3 in the heterodetic 
(depsipeptide) and homodetic (all peptides) forms are known to take up three-fold 
symmetric structures. Some of the examples of such types like the Enniatin B–KI
complex (Dobler et al., 1969), Beauvericin hydrated (Geddes and Akrigg, 1976) in the 
solid state and a solution conformer of c(Pro-Gly)3 and its cation complexes (Madison 
et al., 1974) show a three-fold symmetric structure. Energy calculations have been done 
by Mitra (1978) in this group of cyclic hexadepsipeptides having a three-fold symmetry 
using grid search procedures. Recently energy minimization studies of cyclic hexapep- 
tides having a three-fold symmetry were done. The basic unit for which only one 
hydrogen bonding scheme is possible viz., a 3→ 1 hydrogen bond across the dipeptide. 
Therefore starting with such a stable dipeptide conformation, viz., one in which there is 
a 3→1 hydrogen bond, the possible conformational types of cyclic hexapeptides with 
the three-fold symmetry were worked out. The energy minimization studies show that 
two types of C3-symmetric structures with three 3→1 hydrogen bonds are possible. 
 
(a) One in which three extended conformations are interleaved with the three 3→1 
hydrogen bonded γ-turn or inverse γ conformations.
(b) The other which has alternate y or inverse γ-turn with six 3→1 hydrogen bonds 
and an overall S6 molecular symmetry.
 
Figure 2g,h show the two types of conformations with C3 and S6 symmetry and 
having three and six 3→1 hydrogen bonds respectively.
In the case of c(Pro-Gly)3, the possibility of a two β-turn structure is ruled out owing 
to the presence of the three alternate N–Cδ groups. Therefore the next stable hydrogen 
bonding scheme i.e., the 3→1 hydrogen bond is preferred. Further, since the Pro 
residue is known to induce a 3→1 hydrogen bonded turn, a three 3→1 hydrogen 
bonded structure is expected in c(Pro-Gly)3, one of the solution conformers of c(Pro- 
Gly)3 in nonpolar solvents is known to take up this structure.
Many of the cyclic hexapeptides studied experimentally contain an L-Pro residue 
(Gierasch et al., 1981; Kopple et al., 1973, 1974, 1981, 1983). Since a Pro residue can 
occur as a cis Pro or as a trans Pro form with equal ease, some of the solid state and 
solution structures of cyclic hexapeptides are known to have cis Pro peptide bonds. The 
crystal structures of cyclo (L-Pro-L-Pro-Gly-L-Pro-L-Leu-Gly) (Nakashima et al., 
1984), cyclo (Gly-L-Pro-L-Pro)2 (Czugler et al., 1982) its Mg2+ complex (Karle and 
Karle, 1981) and cyclo (L-Phe-L-Pro-D-Ala)2 (Kartha et al., 1984) have two cis peptides 
in the cyclic hexapeptide backbone. The peptide conformation sequence in the former 
two have cis peptide units occurring consecutively, while those of the latter two are 
separated by two trans units. In addition, the crystal structure of cyclo (L-Pro-Gly)3 
(Kartha et al., 1982) shows one cis peptide unit in the cyclic hexapeptide backbone. The 
occurrence of the cis peptide units as a major conformation in solution has been 
thought of to be dependent on the solvent and the bulkiness of the residue preceding 
Pro (Sarkar et al., 1984; Kopple et al., 1981,1983), for the c(L-A1-L-Pro-D-A3)2 types 
of cyclic hexapeptides. 
 
Cyclic peptides having more than 6 residues 
 
It is quite obvious that as one moves towards big cyclic peptides the conformational 
possibilities and the number of hydrogen bonding schemes increase considerably. Any 
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minimization studies in a multidimensional space is naturally bound to give a large 
number of minima and the selection from among these minima becomes difficult, in the 
absence of established procedures. In the present section, the various observed 
structures of these higher cyclic peptides are looked into to get any useful information 
on the general conformational aspects.
There are three examples of Sarcosyl containing higher cyclic peptides. They are 
cyclo hepta Sarcosyl (Groth, 1975), cyclo(L-Pro-Sar)4 (Shimizu et al., 1983) and cyclo 
deca Sarcosyl (Groth, 1976b). As is to be expected there are a large number of cis 
peptide units in the ring. The ratio of cis: trans in these cases are 4:3, 4:4 and 6:4 
respectively. There are two examples of higher cyclic peptides containing N-methylated 
amino acids. They are Ilamycin B1 (Iitaka et al., 1974), which contains two N-methyl- 
Leu residues and cyclosporin A (Petcher et al., 1976), containing seven N-methylated 
amino acids including one Sarcosyl. The former contains two cis involving the N- 
methylated residues and it is surprising that the latter contains only one cis peptide unit 
inspite of the abundance of N-methyl residues.
From the above it is clear that it is virtually impossible at this stage to predict the 
number of cis peptide units or the sequence of cis and trans residues that occur in these 
cases. 
Regarding the hydrogen bonding in these higher cyclic peptides, Karle (1981a) has 
given detailed description of the types of hydrogen bonds occurring in the crystal 
structures of cyclic peptides. As can be seen from these, the number of hydrogen bonds 
does not increase in proportion to the size of the cyclic peptide. A close examination of 
these structures reveals that, two or three good hydrogen bonds positioned suitably in 
the ring can bring in the necessary folding of the polypeptide chain to form a cyclic 
peptide and also stability to the conformation.
In the cyclic heptapeptide Ilamycin Β (Iitaka et al., 1974) six of the seven peptide units 
are formed by two β-turns and the seventh one is involved in a weak 5→1 hydrogen 
bond. The cyclic octapeptide β-amanitin (Kostansek et al., 1978) has got a pair of 5→1 
hydrogen bonds and each one of these can support four peptide units (in the same way 
as a 4→1 hydrogen bond stabilizes three peptide units). The complexed and 
uncomplexed forms of antamanide and its analogues (Karle et al., 1973, 1979; Karle 
1974a, b, 1977; Karle and Duesler, 1977) brings out the observation that the 
hydrogen bonding is of 4→1 type in complexed and 5→1 type in uncomplexed forms. 
The reason for this can be sought for in the occurrence of the other coordination 
bonds in the complex. Lastly the cyclic dodecapeptide prolinomycin, cyclo(D-Val-L- 
Pro-L-Val-D-Pro)3 (Hamilton et al., 1980) and the pentadecapeptide cyclo (L-Val-L- 
Pro-Gly-L-Val-Gly)3 (Cook et al., 1980) have six and three 4→1 hydrogen bonds 
respectively. 
 
Conclusion 
 
Thus the present analysis based upon the energy minimization studies carried out in 
our group on small cyclic peptides and the available data on crystal structures of small 
and big cyclic peptides indicate the following: 
(i)   The cyclic tri and tetrapeptides are good model compounds to give us the nature
of the peptide units including their flexibility.
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(ii)  In the case of cyclic tetra to hexapeptides the ring gets its stability through 
hydrogen bonding, and in this 4→1 hydrogen bonding is strongly preferred to 
3→1 type. 
(iii)  As the number of units increases, the effect of hydrogen bonding is such that the 
ring gets its stability from a minimum number, two or three only. Hence the 
remaining oxygen atoms can easily take part in coordination bonds with metal 
atoms and thereby form complexes.
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